HC Wainwright Cuts Curis (NASDAQ:CRIS) Price Target to $20.00

Curis (NASDAQ:CRIS) had its price target lowered by HC Wainwright from $26.00 to $20.00 in a research note issued to investors on Friday, Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock.

Curis Trading Down 2.3 %

Curis stock opened at $4.18 on Friday. The firm has a market capitalization of $25.00 million, a P/E ratio of -0.51 and a beta of 3.35. Curis has a twelve month low of $4.05 and a twelve month high of $17.49. The stock’s fifty day simple moving average is $5.28 and its 200-day simple moving average is $7.75.

Curis (NASDAQ:CRIS) last posted its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($2.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.36). Curis had a negative net margin of 468.18% and a negative return on equity of 327.92%. The company had revenue of $2.55 million during the quarter, compared to analyst estimates of $2.20 million. During the same period in the prior year, the business earned ($2.40) EPS. Sell-side analysts predict that Curis will post -6.79 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of Curis by 4.8% during the 1st quarter. Vanguard Group Inc. now owns 218,573 shares of the biotechnology company’s stock worth $2,376,000 after purchasing an additional 10,097 shares during the last quarter. CM Management LLC boosted its position in shares of Curis by 380.0% during the 1st quarter. CM Management LLC now owns 120,000 shares of the biotechnology company’s stock worth $1,304,000 after acquiring an additional 95,000 shares in the last quarter. Point72 Asset Management L.P. increased its holdings in shares of Curis by 795.5% in the 2nd quarter. Point72 Asset Management L.P. now owns 108,356 shares of the biotechnology company’s stock valued at $748,000 after acquiring an additional 96,256 shares during the last quarter. Finally, Focused Wealth Management Inc raised its position in shares of Curis by 63.1% during the 3rd quarter. Focused Wealth Management Inc now owns 54,066 shares of the biotechnology company’s stock worth $291,000 after acquiring an additional 20,908 shares in the last quarter. Hedge funds and other institutional investors own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.